2021-07-27T11:33:41-05:00 2020-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2020-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW No 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2021-07-27 1 Amy Finan 999009999 Jie Chen CPA P01049760 7038930300 2021-07-27 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z Amy Finan 2175 K Street NW No 400 Washington DC 20037 23238847 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 12 11 61 3 0 0 9462400 23177961 0 0 68713 22343 17077 0 9548190 23200304 2584662 7944609 0 0 4288897 6514130 0 0 279144 6886926 6363719 13760485 20822458 -4212295 2377846 12943151 15923054 4012291 4483142 8930860 11439912 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 1 10151266 6390016 Vaccine Research and Development:The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's R&D strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.Ebola has taken the lives of more than 13,000 people in recent years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is developing vaccines based on technology for three clinical-stage candidate vaccines licensed from GSK. The agreement involves prophylactic candidate vaccines to protect against Ebola Zaire, Ebola Sudan and Marburg virus, all based on GSK's proprietary ChAd3 platform. Under other agreements, Sabin is contracted with the Vaccine Research Center at the National Institute of Allergy and Infectious Disease and Biomedical Advanced Research and Development Authority at Health and Human Services to continue development of these vaccines. 8023620 1554593 Global Immunization:Despite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin has a vision of a future free from such preventable diseases. Reaching this goal requires efficient vaccine distribution, broad vaccine uptake and equitable access to vaccination services. Through advocacy, capacity development and social, behavioral, and epidemiological research, Sabin advances evidence-based strategies for improved distribution, equitable access to and uptake of vaccines.Sabin's capacity-development activities help immunization professionals stay up to date on new vaccines, changing policies and recommendations, and developments in vaccine science; and policy makers and the public to discern truth from fiction regarding vaccines and vaccination. Sabin's Boost global community enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts. Sabin's Vaccine Acceptance and Demand workstream helps to dispel misinformation, understand the social drivers of vaccination decisions, and improve social and traditional media effects on vaccine confidence. Sabin drives vaccine innovation by bringing together big thinkers from various industries to accelerate development of a universal influenza vaccine. Through webinars, conferences and workshops Sabin brings together researchers, government officials and immunization specialists at all levels to support the introduction and expansion of new and under-utilized vaccines. Last, Sabin provides and improves surveillance programs and conducts research to generate essential epidemiological data for well-designed and efficiently implemented immunization programs. 18174886 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 32 0 1 61 1 0 0 0 0 0 0 0 0 0 0 0 0 X 12 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2175 K Street NW No 400 Washington DC 20037 Finan Amy Trustee, Officer - CEO; Ex Officio 40.00 X X 410080 0 23484 Baylor Norman Trustee (as of 12/2020) 2.00 X 0 0 0 Dubovsky Filip Trustee (until 08/2020) 2.00 X 0 0 0 Fox Elizabeth Trustee 2.00 X 0 0 0 Holman Wendy Trustee 2.00 X 0 0 0 Hoos Axel Trustee, Chairman (until 12/2020) 2.00 X X 0 0 0 Libson Jeffery Trustee, Secretary (as of 02/2020) 2.00 X X 0 0 0 Omer Saad Trustee 2.00 X 0 0 0 Rabinovich Regina Trustee, Chairwoman (as of 12/2020) 2.00 X X 0 0 0 Salisbury David Trustee 2.00 X 0 0 0 Shea Jacqueline Trustee 2.00 X 0 0 0 Suzich JoAnn Trustee (as of 12/2020) 2.00 X 0 0 0 Thoren Peter Trustee, Vice Chairman 2.00 X X 0 0 0 Davis Brian Officer - COO 40.00 X 335391 0 37266 Gellin Bruce Officer-President,Global Immunization 40.00 X 360080 0 22244 Rustomjee Roxana Senior Vice President, Research & Development 40.00 X 282770 0 45157 Garrett Denise Vice President, Applied Epidemiology Programs 40.00 X 245821 0 27359 Sampath Aruna Vice President, Project Management 40.00 X 236314 0 28798 Hayward Tara Vice President, Resource Development & Policy 40.00 X 208759 0 25224 Woodin Mary Beth Vice President, Communications 40.00 X 200464 0 31183 2279679 0 240715 17 0 1 0 BDO USA LLP PO Box 642743 Pittsburgh PA 152642743 Support R&D QA, PM and gov't compliance 1560425 GTN Holdings LLC PO Box 682 Lebanon NJ 08833 Video production and game development 376712 Eric Martin & Associates 281 West End Road South Orange NJ 07079 Program and advisory support for Boost 260068 Interactive Strategies LLC 1133 Connecticut Avenue NW Suite Washington DC 20036 Web and online platforms 246227 The Aspen Institute 2300 N Street NW Washington DC 20037 Convene stakeholders for VAD program 232604 9 11974260 11203701 23177961 22343 22343 38543 38543 0 23200304 0 0 22343 X 1269977 1269977 6674632 6674632 1188544 1000640 139640 48264 4453629 3839541 432703 181385 147439 81690 59439 6310 387271 224521 148197 14553 337247 204555 118387 14305 75764 37060 38704 14421 14421 4084854 3574458 510176 220 598524 580304 18220 138892 62376 71369 5147 66074 27393 36122 2559 553945 553945 41225 38766 2265 194 195037 187723 7314 365058 252600 112458 58142 9466 48676 Recruitment 87635 71165 13619 2851 Dues/subscriptions 55580 31881 20372 3327 Miscellaneous 26492 4121 22342 29 Books & publications 2076 2017 59 20822458 18174886 2368428 279144 2222415 2245300 5581069 5989051 1739049 4494130 269 40848 197831 210032 1521946 730342 904062 791604 338703 444936 1959753 1707153 12943151 15923054 2087136 2635445 6908 1918247 1847697 4012291 4483142 X 1204781 1815408 7726079 9624504 8930860 11439912 12943151 15923054 X 2377846 24218 106988 X X 0 1 X 1 0 X 14719648 8075830 10410527 9462400 23177961 65846366 14719648 8075830 10410527 9462400 23177961 65846366 32516759 33329607 27774 27008 98272 147130 22343 322527 31650 15222 17077 63949 66232842 21200 0.50320 0.48220 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 20715470 20715470 1000000 250000 0 0 678334 669505 838024 1000000 3185863 4778795 980 59 1039 169584 167376 209506 250000 796466 1194699 1192938 403716 789222 329008 326626 2382 791604 Deferred rent 1395925 Deferred compensation liability 451772 1847697 X 23314078 24218 51013 75231 23238847 -38543 -38543 23200304 20805026 51013 -68445 -17432 20822458 0 20822458 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. Part XI, Line 4b - Other Adjustments: Rental Expense -38,543. Part XII, Line 2d - Other Adjustments: Rental Expense 38,543. Grant Refund -106,988. 1 South Asia 0 0 Grants to recipients located in region Typhoid study sites, Vaccine Acceptance Small Grants Program awardee 1356657 South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, 0 0 Grants to recipients located in region Dengue vaccine effectiveness study & clinical trial site 17463 Sub-Saharan Africa 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 56317 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria,Belgium 0 0 Grants to recipients located in region Bulk drug substance production for ebola/marburg, Vaccine Acceptance Small Grants Program awardee 5244195 0 0 0 0 0 0 6674632 0 6674632 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study sites 632000 EFT South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, Dengue vaccine effectiveness study 17463 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study sites 475000 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study site 205000 EFT Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine Acceptance Small Grants Program awardee 29351 EFT Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium Bulk drug substance production for ebola/marburg 5242500 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 16650 EFT Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine Acceptance Small Grants Program awardee 26966 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 27308 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 699 EFT 10 0 Vaccine Acceptance Small Grants Program awardee Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgiu 1 1695 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). Part III Accounting Method: 1 Batelle Memorial Institute Dept L 998 Columbus OH 43260 314379427 501c3 210172 Non-clinical tests for R&D program Covance Laboratories Inc 3301 Kinsman Blvd Madison WI 53704 540898188 288655 Immunology studies for R&D program ICON Government and Public Health Solutions 1265 Ridge Road Hinckley OH 44233 541716562 313265 Clinical trial oversight for R&D program Integrated Biotherapeutics Inc 4 Research Court Suite 300 Rockville MD 20850 203052840 220144 Critical reagents production for R&D program Johns Hopkins University 12529 Collections Center Drive Chicago IL 60693 520595110 501c3 9450 Social media research and Vaccine Acceptance Small Grants awardee Massachusetts General Hospital 55 Fruit Street GRJ 504 Boston MA 02114 041564655 501c3 30000 Typhoid study site Stanford University Lockbox PO Box 44253 San Francisco CA 94144 941156365 501c3 190000 Typhoid study site 4 3 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 0 0 0 0 0 0 0 0 0 Finan Amy Trustee, Officer - CEO; Ex Officio 374080 0 36000 0 0 0 9928 0 13556 0 433564 0 0 0 Gellin Bruce Officer-President,Global Immunizatio 328080 0 32000 0 0 0 10053 0 12191 0 382324 0 0 0 Davis Brian Officer - COO 302891 0 32500 0 0 0 10084 0 27182 0 372657 0 0 0 Rustomjee Roxana Senior Vice President, Research & De 282770 0 0 0 0 0 9010 0 36147 0 327927 0 0 0 Garrett Denise Vice President, Applied Epidemiology 230821 0 15000 0 0 0 9336 0 18023 0 273180 0 0 0 Sampath Aruna Vice President, Project Management 235814 0 500 0 0 0 5233 0 23565 0 265112 0 0 0 Hayward Tara Vice President, Resource Development 196759 0 12000 0 0 0 7702 0 17522 0 233983 0 0 0 Woodin Mary Beth Vice President, Communications 195464 0 5000 0 0 0 8003 0 23180 0 231647 0 0 0 Form 990, Part III, line 3 In 2020, we combined the Vaccine Acceptance and Demand and the Vaccine Knowledge and Innovation programs under one program titled Global Immunization. Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance and Audit Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Transcription/translation service: Program service expenses 15,025. Management and general expenses 0. Fundraising expenses 0. Total expenses 15,025. Consultants: Program service expenses 3,410,173. Management and general expenses 510,176. Fundraising expenses 220. Total expenses 3,920,569. Contractor: Program service expenses 149,260. Management and general expenses 0. Fundraising expenses 0. Total expenses 149,260. Form 990, Part XI, line 9: Grant refunded 106,988. Form 990, Part XII, Line 2c: The Organization has a Finance and Audit Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.